VYNE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
VYNE Therapeutics Inc is not a strong buy for a beginner investor with a long-term strategy at this time. The lack of clear positive catalysts, weak financial performance, and neutral trading sentiment suggest that it is better to wait for stronger signals or improvements in the company's fundamentals before investing.
The technical indicators show a neutral trend. The MACD is below 0 and negatively contracting, the RSI is neutral at 58.885, and moving averages are converging. Key support and resistance levels are at S1: 0.58, Pivot: 0.602, and R1: 0.623. There is no clear bullish or bearish signal.
Revenue increased by 54.76% YoY in Q4 2025, and gross margin remains at 100%.
Net income dropped significantly by -59.77% YoY, and EPS declined by -60.71% YoY. No recent news or significant trading trends from hedge funds, insiders, or Congress. Stock trend analysis suggests a short-term decline in price.
In Q4 2025, revenue increased to $130,000 (up 54.76% YoY), but net income dropped to -$4,837,000 (down -59.77% YoY). EPS also declined to -0.11 (down -60.71% YoY). Gross margin remained stable at 100%.
No data on analyst ratings or price target changes is available.
